Ignite Creation Date:
2024-05-06 @ 7:36 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06062485
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-10-02
First Post:
2023-09-25
Brief Title:
Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma
Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Organization:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Organization Data
Organization:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Class:
OTHER
Study ID:
HMPL-012-E2-BTC-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None